Director Bode John B bought ZEVRA Therapeutics ($ZVRA) shares on the open market twice in the last year, for a total of about $125,000. His most recent purchase was on August 19, 2025. These buys rank 1,954th among nearly 5,000 insiders, below the average of $1.46 million across 3.29 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | M | Common Stock | 39200 | $4.97 | 84,200.0000 | 56,783,000 | 87.11% | 0.07% |
| March 24, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | M | Stock Option (right to buy) | 39200 | $0.00 | 0.0000 | 56,783,000 | 100.00% | 0.07% |
| March 24, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | M | Stock Option (right to buy) | 39200 | $0.00 | 19,600.0000 | 56,783,000 | 66.67% | 0.07% |
| March 24, 2026 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | M | Common Stock | 39200 | $4.89 | 123,400.0000 | 56,783,000 | 46.56% | 0.07% |
| Jan. 30, 2026 | Newton Golf Company, Inc. | $NWTG | Bode John B | Director | A | Common Stock | 18549 | $0.00 | 18,549.0000 | 4,752,463 | 9999.99% | 0.39% |
| Aug. 19, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 5000 | $9.17 | 45,000.0000 | 47,808,817 | 12.50% | 0.01% |
| May 29, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 47,808,817 | 9999.99% | 0.06% |
| March 19, 2025 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 10000 | $7.96 | 40,000.0000 | 47,808,817 | 33.33% | 0.02% |
| July 12, 2024 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 10000 | $5.87 | 30,000.0000 | 0 | 50.00% | 0.00% |
| May 13, 2024 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | A | Stock Option (right to buy) | 39200 | $0.00 | 39,200.0000 | 0 | 9999.99% | 0.00% |
| Sept. 5, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 10000 | $5.13 | 20,000.0000 | 0 | 100.00% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 2451 | $5.05 | 10,000.0000 | 0 | 32.47% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 1390 | $5.04 | 1,390.0000 | 0 | 9999.99% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 300 | $5.04 | 1,690.0000 | 0 | 21.58% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 1000 | $5.04 | 2,690.0000 | 0 | 59.17% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 4759 | $5.04 | 7,449.0000 | 0 | 176.91% | 0.00% |
| May 18, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | P | Common Stock | 100 | $5.05 | 7,549.0000 | 0 | 1.34% | 0.00% |
| May 3, 2023 | ZEVRA THERAPEUTICS, INC. | $ZVRA | Bode John B | Director | A | Stock Option (right to buy) | 58800 | $0.00 | 58,800.0000 | 0 | 9999.99% | 0.00% |